Vectura wins additional $10m patent damages against GSK
16-09-2019
GSK awarded Arrow declaration in patent dispute with Vectura
17-12-2018
Vectura sues GSK for patent infringement
29-07-2016
Willy Barton / Shutterstock.com
British drugmaker Vectura has succeeded in its patent litigation against fellow UK pharmaceutical company GlaxoSmithKline (GSK) over a series of drugs delivered through GSK’s ‘Ellipta’ dry powder inhaler.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Vectura, GlaxoSmithKline, Ellipta, asthma, patent infringement, chronic obstructive pulmonary disease, damages, royalties, Delaware
